PCOS and Omega-3: Inflammatory Markers and Androgen Profile
No Thumbnail Available
Date
2022
Authors
Journal Title
Journal ISSN
Volume Title
Publisher
Rīgas Stradiņa universitāte
Rīga Stradiņš University
Rīga Stradiņš University
Abstract
Priekšvēsture: policistisko olnīcu sindroms (PCOS) ir izplatīts stāvoklis, kas skar līdz pat 13% sieviešu reproduktīvā vecumā. Pēdējā laikā pieaug interese par omega-3 traukskābju iespējamiem ieguvumiem dažādu slimību ārstēšanā, kā arī par tās lomu PCOS terapijā. Hronisks zemas pakāpes iekaisums un hiperandrogēnisms ir daļa no šī sindroma patoģenēzes, un, tā kā omega-3 piemīt pretiekaisuma īpašības, ir pamats uzskatīt, ka omega-3 spēlē lomu PCOS terapijā. Lai gan ir pierādījumi, ka omega-3 taukskābēm varētu būt labvēlīga ietekme, tās nav iekļauts PCOS ārstēšanas vadlīnijās.
Mērķis: Šī pētījuma mērķis bija novērtēt pašreizējās zināšanas un pierādījumus par omega-3 efektivitāti PCOS pacientu androgēnu profila un iekaisuma marķieru uzlabošanā.
Metodes: tika veikts zināmo klīnisko pētījumu un metaanalīžu pārskats starptautiskās pētījumu datubāzēs. Tika analizēti pētījumi, kas ietvēra informāciju par omega-3 lietošanu PCOS pacientēm un kuros tika izvērtēta to ietekme uz androgēno hormonu līmeņiem un iekaisuma marķieriem. Kopumā šajā pārskatā tika iekļauti 19 klīniskie pētījumi un 5 metaanalīzes. Tika novērtēti 13 klīniskie pētījumi attiecībā uz iekaisuma marķieriem un 14 pētījumi par androgēnu profilu. Daži no šiem pētījumiem ietvēra informāciju gan par iekaisuma marķieriem, gan androgēnu profilu.
Rezultāti:.13 pētījumi uzrādīja uzlabojumus, attiecībā uz androgēnu profilu (testosterona līmeni un hirsutisma rādītāju), deviņos pētījumos uzlabojums netika konstatēts. Septiņu pētījumu rezultātiliecināja par iekaisuma marķieru (hs-CRP, interleikīnu un TNF-α) uzlabošanos, bet astoņos izmaiņas netika konstatētas. Līdz šim veiktos pētījumos ir lielas atšķirības starp intervences perioda ilgumu, omega-3 avotu un devu, dalībnieku iekļaušanas un izslēgšanas kritērijiem.
Secinājums: lai gan nevarēja izdarīt noteiktus secinājumus, ir daudzsološi pierādījumi par omega-3 labvēlīgu ietekmi androgēna profila normalizācijā pēc 6 mēnešu ilgas omega-3 taukskābju lietošanas un iekaisuma marķieru mazināšanā pēc 12 nedēļu ilgas preparātu lietošanas. Nepieciešams turpināt plašākus pētījumus, lai gūtu galīgu atbildi par omega-3 taukskābju ietekmi PCOS ārstēšanā un ilgtermiņa prognozē.
Background: Polycystic ovarian syndrome (PCOS) is a common condition affecting up to 13% of women in reproductive age. Lately rising interest has been seen towards possible benefits of omega-3 in multiple conditions and also its role in the management of PCOS. Chronic low-grade inflammation and hyperandrogenism is a part of pathogenesis in this syndrome, and since omega-3 carries anti-inflammatory characteristics, there is a reason to believe that omega-3 play a role in PCOS’s management. While some evidence shows that there are some beneficiary effects of omega-3, it is not included as part of PCOS management. Aim: The aim of this research is to assess the current knowledge and evidence regarding the effects of omega-3 supplementation on androgen profile and inflammatory markers of PCOS patients. Methods: Literature review of known clinical trials and meta-analyses in scientific databases was performed. Studies which included information about omega-3 supplementation in PCOS patients and had androgenic or inflammatory markers as outcomes, were analyzed. In total, 19 clinical trials and 5 meta-analyses were included in this review. 13 clinical trials were evaluated in regards to inflammatory markers and 14 trial in regards to androgen profile. Some of the studies included information about both, inflammatory markers and androgen profile and were evaluated twice correspondingly to the outcome. Results: 11 studies showed an improvement, 9 did not, in regards of androgen profile (testosterone and hirsutism score). Seven studies showed improvement in inflammatory markers (hs-CRP, interleukins and TNF- α) while eight did not. Current studies demonstrate great variability in the duration of the interventional period, source and dosage of omega-3, as well as in inclusion and exclusion criteria of the participants. Conclusion: Although clear definite conclusion could not be reached, there are encouraging results regarding the efficacy of omega-3 on androgen profile and inflammatory markers of PCOS patients. Particularly when the duration of the treatment is at least 6 months for androgen profile, and 12 weeks for inflammatory markers. Larger scope research is needed to reach a definitive answer on the matter of omega-3 efficacy in PCOS patients.
Background: Polycystic ovarian syndrome (PCOS) is a common condition affecting up to 13% of women in reproductive age. Lately rising interest has been seen towards possible benefits of omega-3 in multiple conditions and also its role in the management of PCOS. Chronic low-grade inflammation and hyperandrogenism is a part of pathogenesis in this syndrome, and since omega-3 carries anti-inflammatory characteristics, there is a reason to believe that omega-3 play a role in PCOS’s management. While some evidence shows that there are some beneficiary effects of omega-3, it is not included as part of PCOS management. Aim: The aim of this research is to assess the current knowledge and evidence regarding the effects of omega-3 supplementation on androgen profile and inflammatory markers of PCOS patients. Methods: Literature review of known clinical trials and meta-analyses in scientific databases was performed. Studies which included information about omega-3 supplementation in PCOS patients and had androgenic or inflammatory markers as outcomes, were analyzed. In total, 19 clinical trials and 5 meta-analyses were included in this review. 13 clinical trials were evaluated in regards to inflammatory markers and 14 trial in regards to androgen profile. Some of the studies included information about both, inflammatory markers and androgen profile and were evaluated twice correspondingly to the outcome. Results: 11 studies showed an improvement, 9 did not, in regards of androgen profile (testosterone and hirsutism score). Seven studies showed improvement in inflammatory markers (hs-CRP, interleukins and TNF- α) while eight did not. Current studies demonstrate great variability in the duration of the interventional period, source and dosage of omega-3, as well as in inclusion and exclusion criteria of the participants. Conclusion: Although clear definite conclusion could not be reached, there are encouraging results regarding the efficacy of omega-3 on androgen profile and inflammatory markers of PCOS patients. Particularly when the duration of the treatment is at least 6 months for androgen profile, and 12 weeks for inflammatory markers. Larger scope research is needed to reach a definitive answer on the matter of omega-3 efficacy in PCOS patients.
Description
Medicīna
Medicine
Veselības aprūpe
Health Care
Medicine
Veselības aprūpe
Health Care
Keywords
Atslēgvārdi: PCOS, omega-3, androgēni, testosterons, iekaisuma marķieri., Keywords: PCOS, omega-3, androgens, testosterone, inflammatory markers.